- Medlab Clinical’s (MDC) patent for depression is formally accepted by the European Patent Office
- The depression patent secures work completed by Medlab in an Australia depression trial, specifically around certain drug substances and their treatment potential for major depressive disorders
- With the European Patent Office’s acceptance, the company expects the patent will be granted within the next three months
- Once the patent is fully granted, the company expects to gain protection in up to 36 jurisdictions across Europe
- Medlab Clinical is up 1.15 per cent, trading at 8.8 cents at market close
Medlab Clinical (MDC) has seen its patent for depression formally accepted by the European Patent Office.
The depression patent secures work completed by Medlab in the Australia Depression trial, specifically around certain drug substances and their treatment potential for major depressive disorders.
With the European Patent Office’s acceptance, the company expects the patent will be granted within the next three months.
Medlab’s previous work saw participants in its study being dosed with both NRGBiotic and an anti-depressant display greater symptom remission over the eight weeks period than those on an anti-depressant alone.
The study also revealed participants taking both NRGBiotic and an anti-depressant had greater proportional increase in quality of life from baseline to eight weeks, and showed greater improvement in non-clinical levels of symptoms.
The company said research has shown approximately one in three patients prescribed an anti-depressant medication are non-responders.
A study on major depressive disorders conducted by MDC showed that using NRGBiotic with an antidepressant produced significantly better and faster outcomes than taking the anti-depressant medication alone.
Once the patent is fully granted, Medlab expects protection in up to 36 jurisdictions across Europe, including Cyprus, Estonia, Lithuania, Luxembourg and Macedonia.
Medlab Clinical was up 1.15 per cent, trading at 8.8 cents at market close.